An important aspect of the combination therapy is that anti-tumor activity was detected using a trastuzumab dose that is within the dose range administered to HER2/neu+ breast cancer patients [39], highlighting the translational potential of this novel combination therapy. Here, ERBB2 is linked to neoplasm.